,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-04-16 22:20:00,St. Jude Medical 's ( STJ ) first-quarter adjusted earnings per share of 92 cents were in line with the Zacks Consensus Estimate and transcended the year-ago earnings of 86 cents.,0.9283275008201599,0.02712462656199932,0.04454786330461502,positive,0.9012028574943542
1,2013-04-16 22:20:00,Adjusted earnings exclude one-time items such as restructuring and acquisition-related charges as well as income tax benefits.,0.009447289630770683,0.027048179879784584,0.9635045528411865,neutral,-0.0176008902490139
2,2013-04-16 22:20:00,Adjusted earnings are within the company's first-quarter guidance of 91-93 cents a share.,0.19248640537261963,0.020826568827033043,0.7866870760917664,neutral,0.17165984213352203
3,2013-04-16 22:20:00,Profit (as reported) for the quarter increased 5.2% year over year to $223 million (or 78 cents a share).,0.9574387073516846,0.019881082698702812,0.022680187597870827,positive,0.9375576376914978
4,2013-04-16 22:20:00,Controlled operating expenses managed to dampen sluggish sales and a difficult Med-Tech environment in the quarter.,0.36191222071647644,0.616516649723053,0.021571092307567596,negative,-0.25460442900657654
5,2013-04-16 22:20:00,The Minnesota-based medical technology giant noted that it is comfortably placed with its earnings results and plans to launch 20 new products in 2013 to salvage its declining top line.,0.9375798106193542,0.022983847185969353,0.03943637013435364,positive,0.9145959615707397
6,2013-04-16 22:20:00,"Revenues dropped 4% (down 3% in constant currency) year over year to $1,338 million in the first quarter.",0.016249246895313263,0.9742242693901062,0.009526442736387253,negative,-0.9579750299453735
7,2013-04-16 22:20:00,"Results were below the Zacks Consensus Estimate of $1,368 million.",0.01839764043688774,0.9597594141960144,0.021843019872903824,negative,-0.9413617849349976
8,2013-04-16 22:20:00,Unfavorable foreign currency lowered total revenue by $17 million.,0.01625395007431507,0.9715498089790344,0.012196177616715431,negative,-0.9552958607673645
9,2013-04-16 22:20:00,"All segments, except the Atrial Fibrillation (AF) business, reported disappointing results, especially the Cardiac Rhythm Management (CRM) unit.",0.01765667460858822,0.9602723717689514,0.022070907056331635,negative,-0.9426156878471375
10,2013-04-16 22:20:00,"Revenues from the CRM division, St. Jude's mainstay, fell 8% (down 7% in constant currency) year over year to $678 million, indicating sustained softness in the CRM market.",0.0179072767496109,0.9727444648742676,0.009348246268928051,negative,-0.9548372030258179
11,2013-04-16 22:20:00,ICD revenues slid 5% (down 4% in constant currency) to $427 million and pacemaker sales plunged 12% (down 11% in constant currency) to $251 million.,0.01635339856147766,0.9732673764228821,0.010379236191511154,negative,-0.956913948059082
12,2013-04-16 22:20:00,"On a positive note, Atrial Fibrillation revenues climbed 5% (up 7% in constant currency) year over year to $233 million.",0.9590731263160706,0.02019917406141758,0.02072770707309246,positive,0.9388739466667175
13,2013-04-16 22:20:00,Neuromodulation sales also dropped 4% (down 4% in constant currency) to $99 million.,0.016331704333424568,0.9742192029953003,0.009449058212339878,negative,-0.9578874707221985
14,2013-04-16 22:20:00,Revenues from the Cardiovascular franchise declined 2% year over year (flat in constant currency) at $328 million.,0.0165616013109684,0.9738701581954956,0.009568251669406891,negative,-0.9573085308074951
15,2013-04-16 22:20:00,"Within Cardiovascular, vascular products sales dipped 3% to $175 million and structural heart product revenues fell 1% to $153 million.",0.016632389277219772,0.9739934206008911,0.00937415286898613,negative,-0.9573610424995422
16,2013-04-16 22:20:00,Gross margin decreased to 71.8% from 72.7% a year ago.,0.018436085432767868,0.9732000827789307,0.008363833650946617,negative,-0.9547640085220337
17,2013-04-16 22:20:00,"Selling, general and administrative expenses, as a percentage of sales, remained roughly flat at 35%.",0.023992540314793587,0.6914423108100891,0.28456512093544006,negative,-0.6674497723579407
18,2013-04-16 22:20:00,Research and development expenses (as a percentage of sales) edged down to 12% from 12.5%.,0.01995166577398777,0.9710021615028381,0.009046160615980625,negative,-0.9510505199432373
19,2013-04-16 22:20:00,"However, it is worthwhile to note that operating margins increased to 23% from 21.6% a year ago, on the back of controlled expenses.",0.9591322541236877,0.025566285476088524,0.015301491133868694,positive,0.9335659742355347
20,2013-04-16 22:20:00,"St. Jude exited the first quarter of 2013 with cash and cash equivalents of $966 million, a year-over-year decrease of 19.1%.",0.019565261900424957,0.9700533151626587,0.01038138847798109,negative,-0.9504880309104919
21,2013-04-16 22:20:00,"Long-term debt increased 11.1% year over year to $2,833 million.",0.9576101899147034,0.019219063222408295,0.023170746862888336,positive,0.9383911490440369
22,2013-04-16 22:20:00,St. Jude has provided its earnings forecast for the second quarter as well as reiterated its guidance for 2013.,0.12761735916137695,0.009546315297484398,0.8628363609313965,neutral,0.1180710420012474
23,2013-04-16 22:20:00,The company expects adjusted earnings for the year in the band of $3.68-$3.73.,0.11753957718610764,0.012519634328782558,0.8699408173561096,neutral,0.1050199419260025
24,2013-04-16 22:20:00,"For the second quarter, it envisions adjusted earnings in the range of 93-95 cents a share.",0.11245240271091461,0.007384115364402533,0.8801634311676025,neutral,0.10506828874349594
25,2013-04-16 22:20:00,"The current Zacks Consensus Estimates for the second quarter and 2013 are 94 cents and $3.70, respectively.",0.0125588895753026,0.031452834606170654,0.9559882879257202,neutral,-0.018893945962190628
26,2013-04-16 22:20:00,"We are concerned regarding St. Jude's declining top-line growth, although the company's plan to introduce new products into the market appears encouraging.",0.4602833688259125,0.40005937218666077,0.13965719938278198,positive,0.06022399663925171
27,2013-04-16 22:20:00,"A still choppy U.S. defibrillator market remains an overhang on St. Jude, as reflected by sustained implant volume pressure.",0.13283942639827728,0.7232969403266907,0.14386357367038727,negative,-0.5904574990272522
28,2013-04-16 22:20:00,"A number of factors, including the Food and Drug Administration (FDA) warning letter, have hindered ICD volume growth.",0.01966359093785286,0.9659229516983032,0.014413532800972462,negative,-0.9462593793869019
29,2013-04-16 22:20:00,We are also cognizant about the ongoing stiff global austerity measures and difficult healthcare environment.,0.07617159187793732,0.4283844530582428,0.4954439401626587,neutral,-0.3522128462791443
30,2013-04-16 22:20:00,"However, the only factor, which helped the company achieve its bottom-line target, was an improved operating margin on the back of the company's restructuring efforts to streamline the underlying business.",0.9571675658226013,0.019563233479857445,0.023269176483154297,positive,0.9376043081283569
31,2013-04-16 22:20:00,St. Jude currently carries a Zacks Rank #4 (Sell).,0.22479240596294403,0.033174507319927216,0.742033064365387,neutral,0.1916179060935974
32,2013-04-16 22:20:00,"While we remain on the sidelines regarding STJ, medical products companies such as NuVasive ( NUVA ), Exactech ( EXAC ) and Perrigo ( PRGO ) are expected to do well.",0.9352802634239197,0.014447947964072227,0.05027180537581444,positive,0.9208323359489441
33,2013-04-16 22:20:00,"While NuVasive carries a Zacks Rank #1 (Strong Buy), the other two are Zacks Rank #2 (Buy) stocks.",0.26182475686073303,0.030540993437170982,0.7076342701911926,neutral,0.2312837690114975
34,2013-04-16 22:20:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
35,2013-04-16 22:20:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
